Vitamin D analogs and methods of preparing these compounds

Details Vitamin D analogs and methods of preparing these compounds Vitamin D analogs and methods of preparing these compounds

1999-06-16

2001-09-11

Qazi, Sabiha (Department: 1616)

Organic compounds -- part of the class 532-570 series

Organic compounds

9,10-seco-cyclopentanohydrophenanthrene ring system or...

C552S653000, C514S167000

Reexamination Certificate

active

06288249

ABSTRACT:

The invention relates to new vitamin D analogs, to methods of preparing these compounds and to their use in pharmacotherapy and cosmetics.
It is generally known, that vitamin-D compounds or vitamin-D related compounds (“vitamin-D analogs”) have a strong biological activity and may be used in all those cases in which problems with the calcium and bone metabolism play a part. A few years ago it was found that various active vitamin-D compounds and analogs also have other pharmacotherapeutic activities and may be used successfully, for example, for the treatment of certain skin and bone diseases, for cosmetic applications and for treating diseases which are related to cell differentiation, cell proliferation or imbalance in the immune system, including diabetes mellitus, hypertension and inflammatory diseases such as rheumatoid arthritis and asthma. In addition, these compounds may be used in various veterinary applications, and for diagnostic purposes.
Further it is known from J. Med. Chem. 38 (1995), 4529-4537 that 1 &agr;, 25-dihydroxy vitamin D
3
analogs of the formula
wherein S
1
is OH, HOCH
2
— or HOCH
2
CH
2
have very low affinities, i.e. no more than 10
−3
the affinity of calcitriol, for the calf thymus vitamin D receptor, and considerable antiproliferative activities in murine keratinocytes.
Surprisingly it has now been found that a group of new vitamin D analogs has an activity of up to 6 times that of calcitriol, i.e. is much more active than the above mentioned known analogs, in the same test (affinity for the calf thymus vitamin D receptor).
The present invention relates to compounds of the general formula
wherein
R
1
is a hydrogen atom or a substituent selected from the group consisting of CH
2
OH, CH
2
CH
2
OH, CH
2
CH
2
CH
2
OH, OCH
3
, OCH
2
OH, OCH
2
CH
2
OH and OCH
2
CH
2
CH
2
OH;
R
2
is a hydrogen atom or a substituent selected from the group consisting of OCH
3
, OCH
2
OH, CH
m
(CH
2
OH)
n
(CH
2
CH
2
OH)
p
, (CH
2
)
q
OH and O(CH
2
)
r
OH;
wherein:
m is 0 or 1, p, q and n are 0-3, r is 1-3 and m+n+p=3;
with the proviso that R
1
and/or R
2
contain at least one OH group;
R
3
is a straight or branched, saturated or unsaturated aliphatic hydrocarbon of 6-13 C atoms which may be substituted with one or more substituents from the group hydroxy or fluoro.
The above new vitamin D analogs of the invention, presented by the general formula I, are valuable substances. The biological results, as illustrated in the Examples, indicate that these compounds are promising as biologically active substances and may be used in all above-mentioned pharmacotherapeutic indications, more in particular for the treatment of osteoporosis, renal osteodystrophy, osteomalacia, skin disorders such as psoriasis (and other hyperproliferative skin diseases), eczema and dermatitis, myopathy, leukaemia, breast and colon cancer, osteosarcomas, squamous cell carcinomas, melanoma, certain immunological disorders, and transplant rejections.
Furthermore, the new vitamin D analogs of the invention may be used for wound healing and may be incorporated in cosmetic compositions, such as creams, lotions, ointments and the like, in order to preserve, condition and/or protect the skin and to improve various skin conditions, such as wrinkles, dry skin, skin slackness and insufficient sebum secretion. The new vitamin D analogs may also be used for diagnostic purposes.
Preferred compounds of the general formula (I) are the compounds wherein R
3
is the group —(CH
2
)
3
—C(CH
3
)
2
OH.
Especially preferred are the compounds of formula (I) wherein R
3
is the group —(CH
2
)
3
—C(CH
3
)
2
OH and wherein:
a) R
1
is a hydrogen atom and R
2
represents CH
2
CH
2
OH, CH
2
CH
2
CH
2
OH, CH(CH
2
CH
2
OH)
2
, C(CH
2
CH
2
OH)
3
or C(CH
2
CH
2
OH)
2
CH
2
OH; or
b) R
1
is OH, CH
2
OH or (CH
2
)
2
OH and R
2
represents hydrogen, OH, OCH
3
, or O(CH
2
)
r
OH, wherein r has the value 1 to 3.
Most particularly preferred are the compounds of formula (I) wherein R
3
is the group —(CH
2
)
3
—C(CH
3
)
2
OH and wherein:
R
1
is hydroxy, CH
2
OH and CH
2
CH
2
OH and R
2
represents hydrogen, CH
2
OH or CH
2
CH
2
OH.
It is a special merit of the present invention that the above new vitamin D analogs can easily be prepared from readily available starting materials.
Consequently, the invention also relates to a method of preparing a vitamin D analog of the general formula I, as defined above, which method is characterized in that a compound of the general formula
wherein:
R
3
′ is a straight or branched, saturated or unsaturated aliphatic hydrocarbon of 6-13 C-atoms which may be substituted with one or more substituents from the group protected hydroxy or fluoro, is reacted with an organometallic compound of the general formula
R
1
′ and R
2
′ are the hydroxy protected analogs of R
1
and R
2
defined above, X is Li,MgCl, MgBr or MgI, to yield a compound of the general formula
followed by dehydration and deprotection of the hydroxy group(s).
The compounds having formula I can also be obtained by reacting a compound of the general formula
wherein R
3
′ has the meaning given above, and R
4
is a protected hydroxy group, with a compound of the general formula
wherein X′ is halogen, preferably Br, and R
1
′ and R
2
′ have the above given meanings, under the influence of an alkyl lithium compound, a zinc halogenide, preferably ZnCl
2
, and a transmetallation catalyst, followed by deprotection of the hydroxy group(s). An example of a transmetallation catalyst is tris-(dibenzylidene-acetone)-dipalladium(0).
The enolic hydroxy group of enolized compound IV is preferably derivatized by a reaction with N-aryltriflimide to produce a triflate.
To improve the applicability of the new vitamin D analogs of the invention for the above-described pharmacotherapeutic indications, the compounds are usually processed to pharmaceutical compositions, comprising an effective amount of said vitamin D analog as the active ingredient in addition to a pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance. Such a composition may be delivered in a dosage unit form for oral, topical (dermal) or parenteral administration, comprising approx. 0.1 &mgr;g to approx. 0.1 mg active ingredient per dosage unit. A composition for diagnostic purposes may comprise, in addition to the vitamin D analog of the present invention, a compatible, non-toxic carrier and/or at least one auxiliary substance.
A cosmetical composition may comprise, in addition to an effective amount (in the range of approx. 0.1 &mgr;g to. approx. 0.1 mg per dosage unit in a dosage unit form) of the vitamin D analog of the present invention, a cosmetically acceptable, non-toxic carrier and/or at least one auxiliary substance.
Finally the invention relates to a method for the treatment and prophylaxis of a number of disease states including autoiummune diseases (including diabetes mellitus), acne, alopecia, skin aging (including photo-aging), imbalance in the immune system, inflammatory diseases such as rheumatoid arthritis and asthma, as well as diseases related to abnormal cell differentiation and/or proliferation, in a warm-blooded living being, comprising administering to said being or treating said being with a pharmaceutical composition as defined above in a quantity effective for the intended purpose. Examples of such diseases are psoriasis and other hyperproliferative skin diseases.
The present invention also relates to the use of the above pharmaceutical compositions for the treatment of solid, skin and blood cancers, in particular of blood cancers such as leukaemia, of breast and colon cancer, and of skin cancers such as melanoma and squamous cell carcinoma.
The above-defined cosmetical compositions, in particular selected from the group consisting of creams, lotions, ointments, liposomes and gels, can be used for the treatment and prevention of a number of skin disorders, such as inadequate skin firmness or texture, insufficient skin hydration, wrinkles and insuf

Affiliated with

Also associated with

Rating

Vitamin D analogs and methods of preparing these compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vitamin D analogs and methods of preparing these compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitamin D analogs and methods of preparing these compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2442727